Tag : INDIVIDUALIZED STARTING DOSE

CONFERENCE UPDATE

Final analysis of NORA demonstrates the OS benefits of niraparib maintenance in Chinese PSROC patients regardless of gBRCAm status
Niraparib is a potent and highly selective poly-ADP ribose polymerase (PARP) inhibitor. PARP inhibitors have shown a trend of favorable overall survival (OS) in platinum-sensitive recurrent ovarian cancer (PSROC) in the maintenance setting. However, this OS benefit appears inconsistent in patients without BReast CAncer gene (BRCA) mutations which has been attributed to confounding factors, such as post-progression therapies.